CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 No DAC Results: Kinetics and Test Reports

Real Peptides Research TeamEditorial

Updated September 23, 202610 min read

56 WORDS

Short answer

Two letters decide almost everything about CJC-1295 no DAC results: D, A, C. Remove the drug affinity complex from the molecule and the reported plasma half-life collapses from something measured in days to something measured in tens of minutes. Same 29-amino-acid backbone. Completely different kinetic profile, and completely different implications for how a study gets designed.

Key takeaways

CJC-1295 no DAC results reflect a plasma half-life commonly reported at roughly 30 minutes, versus days for the albumin-bound DAC version.
Both components of a CJC-1295 no DAC ipamorelin pairing are largely cleared within a day, and no validated half-life figure exists for the fixed blend because it has never been studied as a combination product.
HPLC purity and net peptide content are separate measurements, and a 99% purity figure tells you nothing about how much peptide the vial actually holds.
Mass spectrometry confirms molecular weight near 3367.9 g/mol but cannot distinguish a transposed sequence without MS/MS fragmentation or amino acid analysis.
Ipamorelin is the selective GHS-R1a agonist; GHRP-6 delivers comparable GH release with substantial appetite, cortisol and prolactin confounders attached.
Lot numbers on the vial and the certificate must match, or the certificate documents a different batch entirely.

We supply research-grade peptides to laboratories, and the questions we field about this compound cluster around two things: how fast it clears, and whether the vial actually contains what the label claims. Both are answerable. Neither is answered well by most of what circulates online.

What do CJC-1295 no DAC results look like in published research?

CJC-1295 no DAC results reported in the literature centre on short, sharp increases in growth hormone pulse amplitude rather than sustained elevation. Without the albumin-binding DAC moiety, the analog's plasma half-life is commonly reported at roughly 30 minutes, so it clears within hours. Researchers choose that profile deliberately when pulsatility is the point.

The common oversimplification is that 'no DAC' just means weaker. It doesn't. The four amino-acid substitutions that make this analog resistant to enzymatic degradation are still present; only the albumin tether is gone, which changes duration rather than receptor affinity. This piece covers clearance timelines, how CJC-1295 no DAC results are reported alongside ipamorelin and GHRP-6, what a test report can and cannot prove, and why identical batches behave differently on the bench.

Clearance: what the half-life difference actually means

CJC-1295 no DAC results are short-lived by design. The compound is properly named tetrasubstituted GRF(1-29), and appears in research catalogues as modified GRF 1-29. It carries four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that block degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that dismantles native growth hormone-releasing hormone within minutes. What it lacks is the drug affinity complex, a maleimidopropionic acid linker that covalently binds circulating albumin. That tether is the only reason the DAC version persists.

With the linker attached, prolonged elevation of growth hormone and IGF-1 across days rather than hours was reported in the CJC-1295 pharmacokinetic work published in the Journal of Clinical Endocrinology and Metabolism (PubMed). Remove it and the analog reverts to a half-life commonly cited at around 30 minutes. In practical terms, it is out of circulation within a few hours.

Ipamorelin is the slower half of the pair. It is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, molecular weight roughly 711.9 g/mol) acting at the growth hormone secretagogue receptor 1a, the ghrelin receptor, with a reported half-life in the region of two hours.

So how long does CJC-1295 ipamorelin no DAC stay in your system? In pharmacokinetic terms, both parent compounds are substantially cleared within a day, while downstream IGF-1 movement follows its own slower curve. No single published figure exists for the fixed blend, because the blend has never been characterised as a combination product. Anyone quoting one precise number for it is extrapolating.

Reading a test report without fooling yourself

A CJC-1295 no DAC test report proves less than most buyers assume, and the gap sits in the same two places almost every time.

First, HPLC purity and peptide content are different numbers. Reverse-phase HPLC reports what fraction of the peptide material in the vial is the target sequence, whether that integrates to 98% or 99%. It says nothing about how much of the vial's gross weight is peptide at all. Lyophilised peptides carry trifluoroacetate counterions left over from purification, plus residual water. Net peptide content routinely lands below labelled gross weight unless the certificate states it separately. Two vials with identical purity figures can differ in actual peptide mass.

Second, mass spectrometry confirms mass, not sequence. ESI-MS or MALDI-TOF will confirm a molecular weight near 3367.9 g/mol for tetrasubstituted GRF(1-29), but a peptide with two residues transposed carries exactly the same mass. Only MS/MS fragmentation or amino acid analysis separates them.

A complete cjc-1295 no dac test report should show the chromatogram itself rather than a summary figure, the mass spec trace, retention time, the batch or lot number, and the test date. If the lot number stamped on the vial does not match the lot number on the certificate, the certificate is decoration.

Every compound we synthesise runs through small-batch production with exact amino-acid sequencing, and the matching certificates of analysis are published rather than produced on request. That distinction tells you more than the purity number printed at the top.

Why ipamorelin and GHRP-6 keep appearing in the same study designs

The pairing exists because the two compounds hit different receptors. CJC-1295 no DAC is a GHRH receptor agonist acting on somatotrophs in the anterior pituitary. Ipamorelin and GHRP-6 are growth hormone secretagogue receptor (GHS-R1a) agonists, binding where ghrelin binds. Co-stimulation of both pathways produces a larger growth hormone pulse than either pathway alone, and the secretagogue arm also blunts somatostatin, the inhibitory hormone that caps pulse amplitude. That mechanistic rationale is the entire reason CJC-1295 no DAC results are rarely reported for the analog in isolation.

Ipamorelin and GHRP-6 are not interchangeable. Ipamorelin was characterised as the first highly selective growth hormone secretagogue, releasing GH with markedly less effect on ACTH, cortisol and prolactin than earlier hexapeptides at comparable GH-releasing potency (PubMed). GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, molecular weight roughly 873 g/mol) is potent but promiscuous, with pronounced appetite stimulation through ghrelin signalling alongside measurable cortisol and prolactin movement.

A design intended to isolate GH-axis effects selects ipamorelin. A design interested in ghrelin-mediated appetite signalling may deliberately select GHRP-6. In our experience working with research buyers, the most common reason a comparison between the two arms fails to replicate is that those confounding endocrine variables were never controlled for in the GHRP-6 arm in the first place.

Handling variables that change outcomes between batches

Potency loss in the lab is usually a storage or handling failure, not a synthesis failure. Lyophilised peptide is stable long-term at around -20°C, kept dark and desiccated. Once reconstituted, the solution belongs at 2-8°C, and repeated freeze-thaw cycling is one of the fastest routes to degradation and aggregation.

Two mechanisms account for most unexplained potency drops. Surface adsorption is the first: at low concentrations, peptide binds to glass and plastic container walls, so a meaningful fraction of the material never reaches the assay. Mechanical stress is the second: vortexing or shaking a freshly reconstituted vial shears the peptide and drives aggregation, which is why diluent is introduced slowly down the vial wall rather than directly onto the cake.

Concentration itself is arithmetic, not a recommendation. A 10 mg vial reconstituted with 2 mL of diluent yields 5 mg/mL; the same vial with 5 mL yields 2 mg/mL. That calculation describes what is in the container and nothing more.

The information here is educational and describes laboratory research literature. These compounds are research-use-only, are not FDA-approved drugs, and are not intended for human or veterinary consumption. If an animal health question is what brought you here, talk to their veterinarian rather than to a research peptide supplier.

CJC-1295 No DAC Results Across Common Research Pairings

This table compares the four secretagogue compounds most often referenced in the same literature, using the kinetic and selectivity characteristics reported for each. It matters because the choice between them changes what a study can actually measure.

Compound	Receptor target	Reported plasma half-life	Selectivity profile in the literature	Bottom line
CJC-1295 no DAC (mod GRF 1-29)	GHRH receptor, anterior pituitary	Commonly cited around 30 minutes	DPP-4 resistant, no albumin binding, pulsatile stimulus	Chosen when short, discrete GH pulses are the experimental variable
CJC-1295 with DAC	GHRH receptor, anterior pituitary	Days rather than hours per JCEM pharmacokinetic data	Albumin-bound via maleimidopropionic acid linker	Chosen when sustained exposure and IGF-1 elevation are the endpoint
Ipamorelin	GHS-R1a (ghrelin receptor)	Around two hours	Highly selective, minimal ACTH, cortisol and prolactin effect	The cleanest secretagogue arm when isolating GH-axis effects
GHRP-6	GHS-R1a (ghrelin receptor)	Reported in the range of tens of minutes	Potent but non-selective, strong appetite signalling, cortisol and prolactin movement	Useful for ghrelin and appetite research, noisy for pure GH studies

What If: Research Handling Scenarios

What if a vial shows 99% purity on the certificate but the assay reads low?

Check net peptide content and adsorption before questioning synthesis. Trifluoroacetate counterions and residual water reduce the peptide mass in a vial below the labelled gross weight, and at dilute working concentrations a measurable fraction of peptide binds to glass and plastic surfaces before it reaches the assay. Both effects produce exactly the pattern of a clean chromatogram paired with disappointing bench data.

What if a source publishes a specific CJC-1295 no DAC dosage or a best time to take it?

Treat it as unsourced. Real Peptides does not provide dosing, titration, timing or administration guidance in any form, because these compounds are research-use-only and are not for human or veterinary consumption. Published research describes growth hormone secretion as pulsatile and somatostatin tone as variable, which is why the question recurs, but describing a physiological rhythm is not the same as recommending a protocol, and we will not supply one.

What if the lyophilised powder looks like a thin film rather than a full cake?

Appearance is a poor purity indicator on its own. Small absolute quantities of peptide frequently lyophilise into a thin film, a ring, or a barely visible residue on the vial wall, and that is a function of fill volume and freeze-drying conditions rather than content. Verify against the lot-matched certificate of analysis instead of the visual.

What if a shipment sat at ambient temperature for several days?

Lyophilised peptide tolerates short ambient excursions far better than reconstituted solution, which is why material ships dry. Document the excursion, note it against the lot, and treat the vial as a known variable in the experiment rather than assuming it is either fine or ruined. Reconstituted material exposed above 8°C carries considerably more risk.

The Unglamorous Truth About Before-and-After Claims

Here is the honest answer: CJC-1295 no DAC before and after content is not data. Photographs, forum logs and self-reported CJC-1295 no DAC ipamorelin before and after accounts carry no controls, no baseline IGF-1, no blinding, no verification that the vial contained the labelled compound at the labelled quantity, and no way to separate the peptide from every other variable in that person's life. They are anecdotes about unregulated compounds used outside any research framework. A single lot-matched certificate of analysis tells you more about what you are working with than a thousand of them.

For laboratories sourcing this cluster, Real Peptides supplies CJC-1295 No DAC, Ipamorelin, GHRP-6, GHRP-2, a pre-blended CJC-1295 and Ipamorelin 5mg/5mg vial and a Tesamorelin and Ipamorelin stack as research compounds, with background references on CJC-1295 and ipamorelin, adjacent work in immune system research peptides, and the full research catalogue.

CJC-1295 no DAC results ultimately say more about the experiment than about the peptide. A 30-minute half-life is not a limitation to be engineered around; it is the reason the compound exists, because a pulsatile stimulus is the only kind that resembles endogenous growth hormone secretion at all. The labs producing clean, repeatable data treat the vial as the least interesting variable in the room: documented, cold, sequence-verified, and then forgotten about, so that the design itself is what is actually being tested.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Both parent compounds clear quickly. The no-DAC GHRH analog has a commonly reported plasma half-life of around 30 minutes, and ipamorelin around two hours, so both are largely cleared within a day in pharmacokinetic terms. Downstream IGF-1 movement follows a slower curve, and no validated figure exists for the fixed blend.

The no-DAC form produces short, discrete growth hormone pulses because it lacks the albumin-binding linker, while CJC-1295 with DAC produced prolonged growth hormone and IGF-1 elevation across days in the Journal of Clinical Endocrinology and Metabolism pharmacokinetic work. Receptor affinity is comparable; duration of exposure is what differs.

A complete report shows the reverse-phase HPLC chromatogram rather than a summary purity figure, a mass spectrometry trace confirming molecular weight near 3367.9 g/mol, retention time, the batch or lot number, and the test date. If the lot number does not match the vial, the report documents a different batch.

Real Peptides does not provide dosage, titration or administration guidance of any kind. These compounds are research-use-only, are not FDA-approved drugs, and are not intended for human or veterinary consumption. Quantities described in published studies relate to controlled research settings and are not transferable recommendations.

We do not provide administration timing guidance, because these are laboratory research compounds and not products for human use. Published endocrinology describes growth hormone secretion as pulsatile and somatostatin tone as fluctuating, which is why the question recurs, but that description is not a protocol and should not be read as one.

Both bind the GHS-R1a ghrelin receptor, but ipamorelin was characterised as the first highly selective growth hormone secretagogue, with markedly less ACTH, cortisol and prolactin activity than earlier hexapeptides. GHRP-6 is potent yet non-selective and produces pronounced appetite signalling, making it noisier for studies isolating the growth hormone axis.

They lack controls, baseline hormone measurements, blinding, and any verification that the vial contained the labelled compound at the labelled quantity. They also cannot separate the peptide from diet, training, sleep and every other uncontrolled variable. A lot-matched certificate of analysis carries more information than any number of anecdotal comparisons.

No. HPLC purity describes what fraction of the peptide present is the target sequence, not how much peptide the vial contains. Trifluoroacetate counterions and residual water reduce net peptide content below gross labelled weight, so two vials at identical purity can carry different peptide mass.

Pricing varies widely by quantity, vial size and supplier, so a single figure is not meaningful. What matters more than price is what accompanies the vial: published, lot-matched certificates of analysis, documented small-batch synthesis, and amino-acid sequence verification rather than a summary purity claim alone.

Lyophilised peptide is held at approximately -20°C, kept dark and desiccated. After reconstitution, solutions are refrigerated at 2-8°C, and repeated freeze-thaw cycling should be avoided because it drives degradation and aggregation. Diluent is introduced slowly down the vial wall rather than shaken or vortexed.

No. ESI-MS and MALDI-TOF confirm molecular weight, and a peptide with two residues transposed has an identical mass to the correct sequence. Distinguishing them requires MS/MS fragmentation or amino acid analysis, which is why a certificate showing only a mass number is incomplete verification.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA